| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 72.8 | 35.0 | 50.6 |
| Other income | 1.7 | 0.8 | 2.8 |
| Total income | 74.5 | 35.8 | 53.3 |
| Profit before exceptional items & tax | -1.0 | 0.1 | -8.3 |
| Profit before tax | -1.0 | 0.1 | -8.3 |
| Net profit | 1.1 | 0.1 | -8.5 |
| Operating margin | -1.3% | 0.3% | -15.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +1000.00% |
|---|---|
| Revenue, year on year | +43.90% |
| Operating profit, year on year | +75.70% |
| Operating profit, quarter on quarter | -285.70% |
BSE results filing, NSE: INDRANIB. Figures extracted from the filing.
Indrayani Biotech Ltd: key numbers
- Share price
- ₹10.36
- Market cap
- ₹55.60 Cr
- Revenue (annual)
- ₹137.8 Cr
- Net profit (annual)
- ₹2.16 Cr
- P/E (TTM)
- 32.5×Sector 29.0×
- Promoter holding
- 32.92%-0.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indrayani Biotech Ltd
All →Indrayani Biotech Capital Structure Change
Indrayani Biotech announced its Rights Issue of up to 3.25 crore partly paid-up equity shares at ₹15 per share, aggregating to ₹48.79 Crore.
- Value
- ₹48.79 Cr
Indrayani Biotech Capital Structure Change
Indrayani Biotech Ltd has revised the schedule for its rights issue. The issue will now be open from September 15, 2026, to October 14, 2026.
Indrayani Biotech Management Change
Indrayani Biotech Ltd announced the resignation of Mr. K. Ravichandran as its Secretarial Auditor, effective August 6, 2026. The company will appoint a successor in due course.
Indrayani Biotech Other Announcement
Indrayani Biotech received approval from the Registrar of Companies to extend the deadline for its FY 2025-26 Annual General Meeting by two months, until November 30, 2026.
Indrayani Biotech Q4 FY26 Results: Turns Profitable, Net Profit ₹1 Cr
Indrayani Biotech Ltd reported revenue from operations of ₹37.8 Cr (-25.3% YoY) and net profit of ₹1 Cr for Q4 FY26.
- Key figure
- Net profit ₹1 Cr